UC San Diego

UC San Diego Previously Published Works

Title

Inhibition of Macrophage Ca2+-independent Phospholipase A2 by Bromoenol Lactone and Trifluoromethyl Ketones (*)

Permalink https://escholarship.org/uc/item/5c77t0v8

Journal Journal of Biological Chemistry, 270(1)

ISSN 0021-9258

Authors

Ackermann, Elizabeth J Conde-Frieboes, Kilian Dennis, Edward A

Publication Date 1995

1995

DOI

10.1074/jbc.270.1.445

Peer reviewed

Inhibition of Macrophage Ca^{2+} -independent Phospholipase A_2 by Bromoenol Lactone and Trifluoromethyl Ketones^{*}

(Received for publication, September 23, 1994, and in revised form, October 28, 1994)

Elizabeth J. Ackermann[‡], Kilian Conde-Frieboes[§], and Edward A. Dennis[¶]

From the Department of Chemistry and Biochemistry, Revelle College and School of Medicine, University of California at San Diego, La Jolla, California 92093-0601

A novel Ca²⁺-independent phospholipase A_2 (PLA₂) has recently been purified from the murine macrophage-like cell line P388D₁ (Ackermann, E. J., Kempner, E. S., and Dennis, E. A. (1994) J. Biol. Chem. 269, 9227-9233). This enzyme is now shown to be inhibited by palmitoyl trifluoromethyl ketone (PACOCF₃), arachidonyl trifluoromethyl ketone (PACOCF₃), and a bromoenol lactone (BEL). Both PACOCF₃ and AACOCF₃ were found to inhibit the macrophage PLA₂ in a concentration-dependent manner. PACOCF₃ was found to be ~4-fold more potent than AACOCF₃, with IC₅₀ values of 3.8 μ M (0.0075 mol fraction) and 15 μ M (0.028 mol fraction), respectively. Reaction progress curves in the presence of either inhibitor were found to be linear, and the PACOCF₃·PLA₂ complex rapidly dissociated upon dilution.

BEL was also found to inhibit the macrophage PLA₂ in a concentration-dependent manner, with half-maximal inhibition observed at 60 nm after a 5-min preincubation at 40 °C. Inhibition was not reversed after extensive dilution of the enzyme into assay buffer. Treatment of the PLA₂ with BEL resulted in a linear, time-dependent inactivation of activity, and the rate of this inactivation was diminished in the presence of $PACOCF_3$. In addition, PLA_2 treated with [³H]BEL resulted in the covalent labeling of a major band at M, 80,000. Inactivation of the PLA₂ by 5,5'-dithiobis(2-nitrobenzoic acid) prior to treatment with [³H]BEL resulted in the near complete lack of labeling consistent with covalent irreversible suicide inhibition of the enzyme. The labeling of a M_r 80,000 band rather than a M_r 40,000 band upon treatment with [³H]BEL distinguishes the macrophage Ca²⁺-independent PLA₂ from a previously identified myocardial Ca²⁺-independent PLA₂ and provides strong evidence that the M_r 80,000 protein is the catalytic subunit.

Phospholipase A_2 (PLA₂)¹ has been the focus of considerable research over the years due to its potential involvement in the release of arachidonic acid from membrane phospholipids and creted PLA₂ (sPLA₂). These enzymes are characterized by their low molecular weight, high disulfide bond content, conserved three-dimensional structures, and a requirement for calcium during hydrolysis (for reviews, see Refs. 3 and 4). Recently, a number of unique intracellular cytosolic PLA₂ have been identified and purified that are distinct from the sPLA₂. Two well studied examples are the 85-kDa Group IV cytosolic PLA₂ (cPLA₂) (5, 6) and the M_r 40,000 myocardial Ca²⁺-independent PLA₂ (iPLA₂) (7). In addition, we have also reported the purification of an apparent M_r 80,000 cytosolic Ca²⁺-independent PLA₂ from the macrophage-like cell line P388D (8) Unlike the sPLA₂ very little is known about the

the subsequent production of prostaglandins and leukotrienes

(for review, see Ref. 1). PLA₂ are also thought to play key roles

in phospholipid metabolism, digestion, and various disease

states. Even though it is now evident that they represent a very

large and diverse family of enzymes (for review, see Ref. 2), the

vast majority of the structural and mechanistic information

available is from the Ca²⁺-dependent Group I, II, and III se-

 Ca^{2+} -independent PLA₂ from the macrophage-like cell line P388D₁ (8). Unlike the sPLA₂, very little is known about the catalytic mechanisms of these enzymes, their intracellular roles, or their relationships to one another. This is especially true in the case of the myocardial iPLA₂ and the macrophage iPLA₂. These two enzymes are unique among the known PLA₂ in that they are both modulated by ATP and they both form high molecular weight complexes of ~400,000 (8, 9). Because of these similarities, there has been some uncertainty as to whether they represent similar enzymes modulated by the same regulatory protein (10) or whether they are truly distinct enzymes. Unfortunately, sequences have not been available for either of these two iPLA₂.

One advantageous method for studying and comparing kinetic and chemical mechanisms between enzymes is through the use of inhibitors. Recently, two active site-directed inhibitors have been reported in the literature, arachidonyl trifluoromethyl ketone (AACOCF₃), which reportedly displays specificity for the Group IV cPLA₂ versus the Group II sPLA₂ (11), and a bromoenol lactone (BEL), (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one, which reportedly displays specificity for the myocardial iPLA₂ versus both Group I and III sPLA₂ (12). In this study, we have investigated the action of each of these inhibitors as well as several additional compounds including a new potent inhibitor, palmitoyl trifluoromethyl ketone (PACOCF₃), toward the purified macrophage iPLA₂, and we have utilized [³H]BEL to help identify the catalytic subunit of the macrophage iPLA₂.

EXPERIMENTAL PROCEDURES

^{*} This work was supported in part by National Institutes of Health Grants GM-20501, GM-51606, and HD-26171. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[‡] Recipient of a Department of Education Graduate Assistance in Areas of National Need fellowship.

[§] Recipient of a Deutsche Forschungsgemeinschaft postdoctoral fellowship.

[¶] To whom correspondence should be addressed.

¹ The abbreviations used are: PLA₂, phospholipase(s) A₂; sPLA₂, secreted Ca^{2+} -dependent PLA₂; cPLA₂, cytosolic PLA₂; iPLA₂, Ca^{2+} -independent PLA₂; AACOCF₃, arachidonyl trifluoromethyl ketone; PACOCF₃, palmitoyl trifluoromethyl ketone; BEL, bromoenol lactone; DPPC, dipalmitoylphosphatidylcholine; PAGE, polyacrylamide gel electrophoresis; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid).

Materials—1-Palmitoyl-2- $[1-^{14}C]$ palmitoyl-sn-glycero-3-phosphorylcholine was purchased from Amersham Corp., 1- $[1-^{14}C]$ palmitoyl-2- $[1-^{14}C]$ palmitoyl-sn-glycero-3-phosphorylcholine was purchased from DuPont NEN, and unlabeled phospholipids were purchased from Avanti Polar Lipids, Inc. All other reagents were analytical grade or better. (E)-6-(Bromomethylene)tetrahydro-3-(1- $[4-^{3}H]$ naphthalenyl)-2H-pyran-2-one ($[^{3}H]$ BEL) was the generous gift of Randy H. Weiss,

and Philip Needleman (Monsanto Co., St. Louis, MO) (13). Anandamide (arachidonylethanolamide) (14) was kindly provided by Ester Fride and Raphael Mechoulam (Hebrew University, Jerusalem, Israel). The two palmitoyl anandamide analogs (N-(2-hydroxyethyl)hexadecanesulfonamide and 3-(hexadecanesulfonyl)-2-methoxy-1,3-oxazolidine) were synthesized and will be described elsewhere.² Synthesis of the phospholipid substrate analogs 1-(hexylthio)-2-(hexanoylamine)-1,2-dideoxy-sn-3-phosphocholine and 1-(hexylthio)-2-(hexanoylamine)-1,2-dideoxy-sn-3-phosphothanolamine is described elsewhere (15), and they were provided by Scott Boegeman.

AACOCF₃—AACOCF₃ was prepared according to the general procedure of Boivin et al. (16) with the following modifications. Instead of using an acylchloride, a mixed anhydride was formed in the reaction mixture by the following procedure. 0.50 g of arachidonic acid (1.6 mmol; Aldrich) was dissolved in 25 ml of dichloromethane under a nitrogen atmosphere. 1.3 ml of pyridine (16.4 mmol) and 1.9 ml of trifluoroacetic anhydride (13.1 mmol) were added at room temperature, and the mixture was stirred for 1 h. The solution was cooled in a ice bath followed by the addition of 10 ml of water. Workup with 100 ml of water, extraction of the aqueous phase with 3×30 ml of dichloromethane, and evaporation of the organic phase after drying with sodium sulfate gave 0.35 g (60%) of $AACOCF_3$ after chromatography with ether/hexane (1:2) on silica gel ($R_{\rm F} = 0.67$). Mass spectroscopy (fast atom bombardment) M - 1: 355.2248 (theoretical), 355.2260 (found). ¹H and ¹³C NMR data were consistent with previously published results (11).

 $PACOCF_{3}$ —PACOCF₃ was synthesized in the same manner as described above for the arachidonoyl analog. Using 0.95 g (3.7 mmol) of palmitic acid as starting material yielded 0.68 g (60%) of PACOCF₃ (R_{F} = 51; ether/hexane (1:2)). ¹H NMR (CDCl₃, 300.0 MHz) δ 0.88 (t, 3H), 1.2–1.4 (m, 24H), 1.6–1.7 (m, 2H), and 2.69 (t, 2H); ¹³C NMR (CDCl₃, 75.48 MHz) δ 14.1, 22.4, 22.8, 28.8, 29.3, 29.5, 29.6, 29.7, 29.8, 32.0, 36.4, 115.7 (q, J = 292 Hz), and 191.5 (q, J = 35 Hz).

BEL and 6-Bromo-2-(1-naphthyl)-5-oxohexanoic Acid (Bromomethyl Ketone)—BEL was synthesized as described previously by Daniels et al. (17). For the bromomethyl ketone, 0.10 g (0.3 mmol) of BEL was dissolved in 5 ml of tetrahydrofuran, and 1 ml of 5 M HCl was added. After 1 h of stirring at room temperature, 50 ml of water was added to the reaction mixture, and the aqueous phase was extracted three times with 50 ml of dichloromethane. Drying the organic phase over sodium sulfate, removing the solvent, and chromatography on silica gel gave 14 mg of a clear oil. ¹H NMR (CDCl₃, 300.0 MHz) δ 2.2–2.7 (m, 4H), 3.9 (s, 2H), 4.4 (t, 1H), 7.3–7.6 (m, 4H), 7.7–7.9 (m, 2H), and 8.1 (m, 1H).

Preparation of $P388D_1 Ca^{2+}$ -independent Phospholipase A_2 —The P388D₁ Ca²⁺-independent PLA₂ was purified utilizing an ammonium sulfate precipitation of the whole cell homogenate followed by sequential column chromatography as described previously (8). Mono Q eluents (purified 100,000-fold with a specific activity of ~1.3 μ M/min/mg (8)) were utilized for most experiments. ATP-agarose eluents (purified 26,000-fold with a specific activity of ~0.32 μ M/min/mg (8)) were utilized for the time-dependent inactivation experiments because the Tris buffer present in the Mono Q eluents catalyzed the hydrolysis of BEL (17).

Phospholipase A_2 Assay—Each PLA₂ assay contained 400 μ M Triton X-100, 100 μ M dipalmitoylphosphatidylcholine (DPPC) (containing 200,000 cpm 1-palmitoyl-2-[1-¹⁴C]palmitoyl-sn-glycero-3-phosphorylcholine), 100 mM Hepes, pH 7.5, 5 mM EDTA, and 0.1 mM ATP in a final volume of 500 μ l. The mixed micellar substrate was prepared as described previously (8). Assays were incubated at 40 °C for 30 min with agitation (unless otherwise indicated), and the reaction was stopped by the addition of 2.5 ml of Dole reagent (2-propanol, heptane, 0.5 M H₂SO₄ (400:100:20, v/v/v)) (18). The product mixture was subsequently processed according to the modified (19) Dole extraction system (18) as described previously (20). Control reactions lacking enzyme were routinely carried out and subtracted from the reported activities.

Inhibition with Trifluoromethyl Ketones—Stock solutions and serial dilutions of inhibitors and fatty acids were prepared in Me₂SO. Each assay tube was prepared by the addition of 5 μ l of the appropriate inhibitor to 445 μ l of the mixed micellar substrate followed by vortexing, bath sonication, and vortexing (30 s each). Assays were initiated by the addition of 50 μ l of the P388D₁ Ca²⁺-independent PLA₂ (sufficient to produce ~3000 counts in 30 min) to the substrate mixture and were incubated at 40 °C for 30 min. Time course experiments were carried out in a similar fashion with variable incubation times. Inhibitor concentrations expressed as mole fractions were calculated utilizing the

total concentration of lipid present in the assay (*i.e.* 100 μ M DPPC and 400 μ M Triton X-100 plus the inhibitor concentration). Because under our assay conditions the monomeric concentration of Triton X-100 is not known, we did not take it into account in calculating the mole fractions reported herein (21).

Inhibition with BEL—Stock solutions and serial dilutions of BEL were prepared in Me₂SO. The P388D₁ Ca²⁺-independent PLA₂ (sufficient to produce 3000 cpm in 30 min) was preincubated with the indicated amounts of BEL in 10 mM Tris (or 10 mM Hepes), pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1 mM ATP, 1 mM Triton X-100, and 10% glycerol. Preincubations were carried out at 40 °C for 5 min with agitation in a volume of 55 μ l. The remaining enzyme activity was assayed by the addition of 445 μ l of substrate mixture followed by incubation at 40 °C for 30 min. The reactions were stopped and processed as described above. The time course of inactivation was carried out in the same manner, except that preincubation times were varied as indicated.

For the competition experiments, PACOCF₃ and BEL were added simultaneously to the enzyme and incubated as described above. Upon dilution into the assay mixture, the concentration of PACOCF₃ was $\sim 1.1 \ \mu$ M, a concentration that results in $\sim 16\%$ inhibition of the PLA₂ activity (see Fig. 1). For a control, the PLA₂ was routinely preincubated in the presence of PACOCF₃ alone, and the resulting activity (measured after dilution into the assay mixture) was defined as 100% of control for all assays in which PACOCF₃ was present.

For dilution experiments, the PLA₂ was concentrated ~6-fold using a Centricon 10 apparatus (Amicon, Inc.). The resulting enzyme preparation was preincubated at 40 °C for 5 min with either Me₂SO alone or 10 μ M BEL and Me₂SO. After preincubation, a 2- μ l aliquot was removed and diluted 1500-fold into 3 ml of assay buffer containing 400 μ M Triton X-100, 100 μ M DPPC (with 200,000 cpm 1-palmitoyl-2-[1-¹⁴C]palmitoylsn-glycero-3-phosphorylcholine/50 μ l of assay buffer), 100 mM Hepes, pH 7.5, 0.8 mM ATP, 1.0 mM dithiothreitol, and 5 mM EDTA. At the indicated time intervals, a 50- μ l aliquot was removed, and the released radiolabeled fatty acid was measured as described above.

Coulent Modification of P388D₁ Ca²⁺-independent PLA₂ by [³H]BEL—~2–3 μ g of the P388D₁ Ca²⁺-independent PLA₂ was incubated with 2 μ M [³H]BEL for 30 min at 40 °C. Excess unreacted [³H]BEL along with the Triton X-100 was removed through four cycles of concentration and dilution utilizing a Centricon 10 apparatus. Samples were subsequently lyophilized, resuspended in sample buffer, and separated by SDS-polyacrylamide gel electrophoresis (PAGE) on a prepoured 10% gel (Novex). Gels were fixed with 50% methanol and visualized by autoradiography. Experiments utilizing the DTNB-inactivated enzyme (P388D₁ PLA₂ preincubated with 1.0 mM DTNB at 40 °C for 15 min) were carried out in a similar fashion, expect that 1–2 μ g of enzyme was utilized and the fixed gels were soaked for 30 min in Amplify (Amersham Corp.) prior to visualization.

Control experiments were also carried out that demonstrated that under these conditions, [³H]BEL inhibited \sim 83% of the PLA₂ activity. For these experiments, the PLA₂ activity was assayed utilizing a double-labeled phospholipid (1-[1-¹⁴C]palmitoyl-2-[1-¹⁴C]palmitoyl-*sn*-glycero-3-phosphorylcholine), and the activity was measured by following the release of 1-[1-¹⁴C]palmitoyl-2-lyso-*sn*-glycero-3-phosphorylcholine separated by TLC as described previously (8). This method was used because the presence of [³H]BEL would have interfered with the detection of released radiolabeled fatty acid in the Dole extraction method.

RESULTS

Inhibition by Trifluoromethyl Ketones-Fig. 1 shows the concentration-dependent inhibition of the P388D₁ Ca²⁺-independent PLA₂ by trifluoromethyl ketone analogs of palmitic acid $(PACOCF_3)$ and arachidonic acid $(AACOCF_3)$ using a mixed micelle assay system with 400 µM Triton X-100 and 100 µM DPPC (4:1 molar ratio of Triton to phospholipid). The saturated analog of AACOCF3 was also synthesized, but it could not be utilized in these experiments due to its low solubility. Also shown in Fig. 1 are the results obtained with the free fatty acids palmitate and arachidonate, which were not inhibitory. Interestingly, PACOCF₃ was found to be \sim 4-fold more potent than AACOCF₃, with an IC₅₀ of 3.8 μ M (0.0075 mol fraction) compared with 15 μ M (0.028 mol fraction) for AACOCF₃. This selectivity is consistent with the substrate preference found earlier utilizing mixed micellar substrates in which the rate of hydrolysis for dipalmitoylphosphatidylcholine was \sim 4-fold faster than that for 1-palmitoyl-2-arachidonoyl-sn-

² K. Conde-Frieboes and E. A. Dennis, manuscript in preparation.




FIG. 1. Concentration-dependent inhibition of the P388D₁ Ca²⁺-independent PLA₂ by PACOCF₃ and AACOCF₃. The P388D₁ PLA₂ was assayed in the presence of increasing concentrations of PACOCF₃ (\blacksquare), AACOCF₃ (\bullet), palmitic acid ($| \lor \rangle$), or arachidonic acid ($| \blacktriangle \rangle$) utilizing a mixed micelle assay containing Triton X-100 and DPPC. The enzyme activity is plotted as the percentage of the control enzyme assayed in the absence of inhibitor. Each point represents the average of duplicates.

glycerol-3-phosphorylcholine (8).

Because $AACOCF_3$ has recently been shown to be a slow, tight-binding inhibitor of the Group IV cPLA₂ (11), we examined the time course and reversibility of inhibition with the $P388D_1\ Ca^{2+}\mbox{-independent}\ PLA_2.$ The $P388D_1\ PLA_2$ was assayed in the presence of either 8 μ M PACOCF₃ or 12 μ M AA- $COCF_3$ or in the absence of inhibitor. As shown in Fig. 2, linear progress curves were observed under all three conditions, with each curve passing through the origin, indicating that these are not slow binding inhibitors. In addition, preincubation of the $P388D_1\ Ca^{2+}\mbox{-independent}\ PLA_2$ with 300 $\mu{\mbox{\tiny M}}\ PACOCF_3$ for 5 min at 40 °C followed by a 1500-fold dilution into assay buffer resulted in near complete recovery of the PLA₂ activity at all time points measured (15-240 min). This is in contrast to the slow dissociation rate observed for the Ca²⁺·AACOCF₃·cPLA₂ complex, where under similar conditions, only 14% of the complex dissociated over a 5-h period (11). Thus, the association/ dissociation rates observed between these inhibitors and the P388D₁ PLA₂ appear to be much faster than the rates observed between the Group IV cPLA₂ and AACOCF₃.

Concentration-dependent Inhibition of $P388D_1 Ca^{2+}$ -independent PLA_2 by BEL—BEL was found to be a potent inhibitor of the purified $P388D_1 Ca^{2+}$ -independent PLA_2 . As shown in Fig. 3, preincubation of the $P388D_1 PLA_2$ for 5 min at 40 °C with increasing amounts of BEL resulted in a concentration-dependent inhibition of activity. Half-maximal activity was found at ~60 nm BEL. In contrast, similar experiments carried out utilizing the hydrolyzed form of the inhibition of the PLA_2 activity at concentrations up to 700 nm (see "Discussion"). Because BEL has been shown to be a suicide inhibitor of the myocardial iPLA_2, we investigated the mechanism of inhibition with the P388D_1 iPLA_2.

Irreversible Inhibition—The reversibility of inhibition could not be assessed using either gel filtration or dialysis techniques due to the presence of Triton X-100 with the enzyme, which was necessary for stabilization of the PLA_2 activity (8). Instead, the $P388D_1 PLA_2$ was preincubated in the presence or absence of BEL and subsequently diluted 1500-fold into assay buffer. Aliquots were removed at various time intervals, and the enzyme activity was determined. As shown in Fig. 4, enzyme not treated with inhibitor resulted a linear time course over the entire assay period, while enzyme pretreated with BEL did not regain any measurable activity in the 4 h following dilution,




FIG. 2. Reaction progress curves of the P388D₁ Ca²⁺-independent PLA₂ in the presence of trifluoromethyl ketone inhibitors. The P388D₁ PLA₂ was assayed under standard assay conditions in the absence of inhibitor (\bullet) or in the presence of either 12 μ M AACOCF₃ (\blacksquare) or 8 μ M PACOCF₃ ($[\bullet]$). Each point represents the average of duplicates.




FIG. 3. Concentration-dependent inhibition of the P388D₁ Ca²⁺-independent PLA₂ by BEL. The P388D₁ PLA₂ was incubated with the indicated concentrations of BEL for 5 min at 40 °C in buffer containing 10 mM Tris, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1 mM Triton X-100, 10% glycerol, and 1 mM ATP. After this preincubation, the enzyme was diluted ~10-fold into the assay mixture, and the remaining activity was measured. Each point represents the average of duplicates and is plotted as the percent of control (enzyme preincubated in the absence of inhibitor).

indicating tight or covalent inhibition of the enzyme by BEL. It should be noted that the enzyme used for the dilution studies was initially concentrated ~6-fold, and therefore, the Triton X-100 present with the enzyme was also concentrated. We have found that in the presence of high concentrations of Triton X-100, higher concentrations of BEL were required in order to achieve full inhibition of the P388D₁ PLA₂ activity. Consequently, 10 μ M BEL was utilized in these experiments to ensure complete inactivation of the enzyme. Whether this phenomenon is due to a protection of the enzyme by Triton X-100 or a partitioning effect is unknown at this time.

Time-dependent Inactivation and Protection by $PACOCF_3$ — To explore the characteristics of this inhibition, the time course of inactivation was examined. The $P388D_1 PLA_2$ was preincubated with BEL for periods of 1–30 min, followed by dilution into the assay mixture and quantification of remaining activity. A semilogarithmic plot of the remaining activity versus preincubation time resulted in a linear inactivation time course (Fig. 5) for each concentration tested up to at least 7 min, indicating pseudo first-order kinetics. This time-dependent inactivation is




FIG. 4. Irreversible inhibition of the P388D₁ Ca²⁺-independent PLA₂ by BEL. The P388D₁ PLA₂ was preincubated at 40 °C for 5 min with either 10 μ M BEL in Me₂SO (**II**) or Me₂SO alone (**II**). After preincubation, a 2- μ l aliquot was removed and diluted 1500-fold into 3 ml of assay buffer. At the indicated time intervals, a 50- μ l aliquot was removed, and the amount of released radiolabeled fatty acid was determined. Each point represents the average of duplicates.




FIG. 5. Time-dependent inactivation of the P388D₁ Ca²⁺-independent PLA₂ by BEL. The P388D₁ PLA₂ was preincubated with 30 nM BEL (\bigcirc), 60 nM BEL (\bigtriangledown), or 100 nM BEL (\bigcirc) for the indicated time periods at 40 °C, followed by dilution into assay buffer and quantification of remaining activity. Each point represents the average of duplicates and is plotted on a semilogarithmic plot as the percent of control enzyme incubated in the absence of inhibitor.

indicative of a direct binding of the inhibitor to the enzyme. At longer preincubation times (7–30 min), first-order kinetics were no longer observed. This is most likely due to a depletion of the inhibitor concentration to a point below or equal to the enzyme concentration (22). In addition, the initial steady-state rate was apparently preceded by a burst of inhibition as evidenced by the lack of intersection at 100% activity for any of the concentrations tested. Suicide inhibition of both the myocardial PLA₂ and chymotrypsin by BEL also resulted in a similar burst of inhibition (12, 23).

Time-dependent experiments were also carried out in the presence of the reversible inhibitor PACOCF₃. The P388D₁ PLA₂ was preincubated with BEL alone or with BEL and 10 μ M PACOCF₃. As shown in Fig. 6, the rate of inactivation in the presence of PACOCF₃ was significantly less than that observed in its absence. This protection afforded by PACOCF₃ suggests that the binding sites on the enzyme for these two inhibitors are at least partially overlapping.

Covalent Labeling of $P388D_1 Ca^{2+}$ -independent PLA_2 with $[^3H]BEL$ —Finally, we examined the ability of $[^3H]BEL$ to covalently label the $P388D_1 PLA_2$. The $P388D_1 PLA_2$ was preincubated with $[^3H]BEL$, the excess inhibitor was removed, and the preparation was separated by SDS-PAGE. As shown in Fig. 7A, a single major band was visualized upon autoradiography




FIG. 6. Protection of the P388D₁ Ca²⁺-independent PLA₂ from inhibition by BEL. The P388D₁ PLA₂ was preincubated with 100 nM BEL in the presence (\bullet) or absence (\blacksquare) of 10 μ M PACOCF₃ for the indicated time periods at 40 °C, followed by dilution into the assay mixture and quantification of remaining activity. These results are expressed relative to the control rate measured in the presence of Me₂SO (for \blacksquare) or Me₂SO plus PACOCF₃ (for \bullet) and are plotted on a semilogarithmic plot. Each point represents the average of duplicates.

at M_r 80,000. This molecular weight correlated with that observed previously in purified preparations of the P388D₁ PLA₂ after SDS-PAGE and silver staining (8). This result is in contrast to that obtained with the myocardial PLA₂ in which [³H]BEL labeled the myocardial M_r 40,000 catalytic subunit (12). In addition to the M_r 80,000 band, we also observed a diffuse band near the top of the autoradiogram. This band was located near the junction between the stacking and running gels and therefore is most likely due to aggregated protein that did not enter the gel.

A similar experiment was also carried out utilizing enzyme that had been treated with DTNB prior to inhibition with ^{[3}H]BEL. Treatment of the P388D₁ Ca²⁺-independent PLA₂ with 1 mm DTNB resulted in the complete loss of PLA₂ activity. As shown in Fig. 7B, utilization of this DTNB-inactivated enzyme resulted in the near complete lack of covalent binding of $[^{3}H]BEL$ to the M, 80,000 protein, as well as the complete lack of the label at the top of the gel, suggesting the necessity for a catalytically competent enzyme for incorporation of label. It should be noted that visualization for the experiment shown in Fig. 7B was carried out utilizing fluorography and therefore resulted in a much higher degree of sensitivity than that observed in Fig. 7A. As can be seen, under these more sensitive conditions, the M_r 80,000 band appears much darker and even overloaded, and there is also a previously unobserved very faint band near the bottom of the gel at $M_r \sim 36,000$. Because this band is only a very small fraction of the total label and was only detected under these more sensitive conditions, it is most likely the result of a degradation product or contamination with another protein that reacts with BEL.

Other Inhibitors—During the course of our studies, we have also investigated the action of several other potential inhibitors on the P388D₁ Ca²⁺-independent PLA₂. Each of these compounds gave an estimated IC₅₀ value of >50 μ M (~10 mol %) and therefore were not pursued further. They include nordihydroguaiaretic acid, anandamide (arachidonylethanolamide), two analogs of anandamide (N-(2-hydroxyethyl)hexadecanesulfonamide and 3-(hexadecanesulfonyl)-2-methoxy-1,3-oxazolidine), and two phospholipid substrate analogs (1-(hexylthio)-2-(hexanoylamine)-1,2-dideoxy-sn-3-phosphocholine and the corresponding phosphoethanolamine), which are potent inhibitors of the Group I PLA₂ (15).




FIG. 7. Covalent modification of the P388D₁ Ca²⁺-independent PLA₂ by [³H]BEL and its attenuation with DTNB-inactivated enzyme. A, ~2–3 μ g of the P388D₁ PLA₂ was incubated with 2 μ M [³H]BEL for 30 min at 40 °C, followed by separation by SDS-PAGE on a 10% gel and visualization by autoradiography. B, control (–) or DTNB-inactivated (+) P388D₁ PLA₂ (1–2 μ g) was incubated with 2 μ M [³H]BEL for 30 min at 40 °C. Samples were subsequently separated by SDS-PAGE on a 10% gel and visualized by fluorography.

DISCUSSION

Trifluoromethyl Ketones: $P388D_1$ iPLA₂ Versus Group IV cPLA₂ Specificity—Recently, Street *et al.* (11) have reported the inhibition of the 85-kDa cytosolic Group IV cPLA₂ by a trifluoromethyl ketone analog of arachidonic acid (AACOCF₃). AACOCF₃, which presumably binds directly to the active site of the cPLA₂, was found to be a slow and tight-binding inhibitor as demonstrated by nonlinear progress curves and a very slow dissociation rate. From these experiments, an upper estimate for the K_i value was estimated at 5×10^{-5} mol fraction. When compared with the 0.1 mol fraction estimated for the sPLA₂, it was apparent that AACOCF₃ is a selective inhibitor for the cPLA₂ versus the sPLA₂.

Results reported herein demonstrate that the P388D₁ PLA₂ is also inhibited by AACOCF₃ as well as a new analog, PACOCF₃. Inhibition was found to be concentration-dependent, with IC₅₀ values of ~0.028 and 0.0075 mol fractions, respectively. Competition experiments carried out in the presence of BEL demonstrate that this inhibition is mediated through a direct binding of the inhibitor to the enzyme, most likely at the active site, consistent with results obtained with the cPLA₂. However, in contrast to the Group IV cPLA₂, kinetic experiments reveal linear progress curves in the presence of both inhibitors, and the PACOCF₃·PLA₂ complex was found to rapidly dissociate upon dilution. Taken together, these data are consistent with a classical mechanism of reversible inhibition.

These data represent the first report of inhibition of a Ca²⁺independent PLA₂ by trifluoromethyl ketone inhibitors. It is difficult to directly compare the exact potency of inhibition between the macrophage iPLA₂ and the cPLA₂ due to the different types of inhibition observed. In addition, it should be kept in mind that the IC_{50} values reported for the macrophage iPLA₂ are a function of the assay conditions utilized and should only be taken as an upper limit estimate of the true K_i value, which may be much lower. In any case, the ability of these compounds to inhibit multiple intracellular PLA₂ in the low micromolar range indicates that their use as specific inhibitors for in vivo studies should be carried out with some caution. For example, the P388D₁ macrophages contain a Group IV cPLA₂, a Group II sPLA₂, and the Ca²⁺-independent iPLA₂ (24), and therefore, these inhibitors cannot be used indiscriminately in this cell type to inhibit specifically either the Group IV cPLA₂ or the Ca²⁺-independent iPLA₂. On the other hand, AACOCF₃ has been used recently in calcium ionophore- and thrombinstimulated platelets to implicate the involvement of the cPLA₂ rather than the $sPLA_2$ in arachidonic acid release (25, 26). Structure/function studies were also carried out with several

different compounds besides $AACOCF_3$ to help eliminate nonspecific inhibition effects (25, 26).

BEL: P388D1 PLA2 Versus Myocardial PLA2-The macrophage iPLA₂ and the myocardial iPLA₂ are unique among the known PLA₂ in that they are both modulated by ATP, and they both form oligometric complexes of $M_r \sim 400,000$ (8, 9). Despite these similarities, there has been some uncertainty as to whether they are similar enzymes modulated by the same regulatory protein or whether they are truly distinct enzymes. For example, in the case of the myocardial PLA₂, these characteristics are thought to be due to the regulation of the M_r 40,000 catalytic PLA₂ by phosphofructokinase (10), a tetrameric enzyme composed of M_r 85,000 subunits. Together, the myocardial PLA₂ and the phosphofructokinase are thought to form an ATP-sensitive regulatory complex, composed of one M_r 40,000 PLA₂ subunit and four M_r 85,000 phosphofructokinase regulatory subunits. The P388D1 PLA2, on the other hand, is thought to be a M_r 80,000 protein that is active as a tetramer (radiation inactivation experiments indicated a catalytically active complex of 337 ± 25 kDa), and it is thought to bind ATP directly (8). However, in our previous studies (8), we were unable to completely rule out a model in which the M_r 80,000 P388D, protein is actually phosphofructokinase that was purified along with an undetected M_r 40,000 catalytic subunit, in analogy with the myocardial PLA₂.

Recently, BEL has been shown to be a potent suicide inhibitor of the myocardial PLA₂ (12, 27). This inhibition was found to be at least 1000-fold more potent toward the myocardial PLA₂ than toward the Group I or III sPLA₂ (12). Because of the similarities between the myocardial PLA2 and the macrophage PLA_2 , we examined the ability of BEL to inhibit the $P388D_1$ PLA₂ in the hope of gaining insight into the relationship between these two enzymes. We have found that (a) BEL is a potent inhibitor of the P388D₁ iPLA₂, with half-maximal activity found at 60 nm after a 5-min preincubation at 40 °C; (b) inhibition is irreversible when subjected to a 1500-fold dilution and covalent as demonstrated by the incorporation of [³H]BEL, which persisted through SDS-PAGE treatment; (c) inhibition is time-dependent and shows pseudo first-order kinetics; (d) this time-dependent inactivation is slowed in the presence of the reversible inhibitor PACOCF₃; and (e) a catalytically active enzyme is necessary for covalent modification as DTNB-inactivated PLA₂ had a greatly diminished capacity for incorporation of label.

Taken together, these data indicate that BEL is a covalent irreversible inhibitor of the P388D₁ PLA₂, with inactivation proceeding through an enzyme-mediated process. These results are consistent with the documented cases of suicide inhibition utilizing BEL with both the myocardial PLA₂ (12) and chymotrypsin (17). In addition, we have found that the hydrolyzed form of BEL (bromomethyl ketone) is not inhibitory. This indicates that the bromomethyl ketone (which is proposed to be the reactive species responsible for irreversible modification of both the myocardial PLA₂ and chymotrypsin) is not released from the enzyme prior to irreversible inactivation, i.e. ruling out a metabolically activated mechanism (22). Furthermore, the sensitivities and characterizations of BEL inhibition observed with the P388D1 PLA2 were strikingly similar to those observed with the myocardial PLA₂. Both enzymes were inhibited by BEL in the nanomolar range, both showed an initial burst of inhibition followed by a first-order time-dependent inactivation, and both enzymes lost their ability to incorporate [³H]BEL label after inactivation with DTNB. These data are intriguing in that they suggest that these two enzymes may share very similar active-site environments.

However, despite these similar sensitivities to BEL, treat-

ment of the macrophage PLA_2 with [³H]BEL resulted in the labeling of a single major M_r 80,000 protein, as opposed to the M_r 40,000 band documented with the myocardial PLA₂. These data distinguish the macrophage PLA₂ from the myocardial PLA₂ and provide strong evidence that the M_r 80,000 protein is the catalytic subunit, and not phosphofructokinase. Thus, the ATP activation and oligomerization observed with both of these enzymes appear to be a function of distinct regulatory mechanisms.

In conclusion, we have demonstrated that PACOCF₃, AA- $COCF_3$, and BEL inhibit the macrophage Ca^{2+} -independent PLA₂ activity. Based on the data presented herein and in analogy with results obtained with the cPLA₂ and the myocardial $iPLA_2$, we propose that the trifluoromethyl ketones are classical reversible inhibitors of the macrophage iPLA₂ and that BEL is a suicide inhibitor. More important, these data demonstrate that the myocardial iPLA₂ and the macrophage iPLA₂ are distinct enzymes and provide new evidence that the M_r 80,000 protein is the macrophage iPLA₂ catalytic subunit.

Acknowledgments-We thank Laure Reynolds and Raymond Deems for critical suggestions and discussions during the course of this study. We also thank Dr. Richard Ulevitch and Lois Kline (Research Institute of Scripps Clinic) for generously growing the P388D₁ cells.

REFERENCES

- 1. Dennis, E. A. (1987) Bio/Technology 5, 1294-1300
- Dennis, E. A. (1994) J. Biol. Chem. 269, 13057-13060 2
- Dennis, E. A. (1983) in The Enzymes (Boyer, P. D., ed) pp. 307-353, Academic 3. Press, New York
- Verheij, H. M., Slotboom, A. J., and de Haas, G. H. (1981) Rev. Physiol. Biochem. Pharmacol. 91, 91-203
- Clark, J. D., Milona, N., and Knopf, J. L. (1990) Proc. Natl. Acad. Sci. U. S. A. 5 87, 7708-7712

- 6. Kramer, R. M., Roberts, E. F., Manetta, J., and Putnam, J. E. (1991) J. Biol. Chem. 266, 5268-5272
- Hazen, S. L., Stuppy, R. J., and Gross, R. W. (1990) J. Biol. Chem. 265. 7 10622-10630
- Ackermann, E. J., Kempner, E. S., and Dennis, E. A. (1994) J. Biol. Chem. 8 269, 9227-9233
- 9. Hazen, S. L., and Gross, R. W. (1991) J. Biol. Chem. 266, 14526-14534
- 10. Hazen, S. L., and Gross, R. W. (1993) J. Biol. Chem. 268, 9892-9900
- 11. Street, I. P., Lin, H. K., Laliberte, F., Ghomashchi, F., Wang, Z., Perrier, H. Tremblay, N. M., Huang, Z., Weech, P. K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940
- Hazen, S. L., Zupan, L. A., Weiss, R. H., Getman, D. P., and Gross, R. W. (1991) J. Biol. Chem. 266, 7227-7232
- Durley, R. C., Parnas, B. L., and Weiss, R. H. (1992) J. Labelled Compd. 13. Radiopharm. XXXI, 685-691
- 14. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992) Science 258, 1946-1949
- Plesniak, L. A., Boegeman, S. C., Segelke, B. W., and Dennis, E. A. (1993) 15. Biochemistry 32, 5009-5016
- 16. Boivin, J., Kaim, L. E., and Zard, S. Z. (1992) Tetrahedron Lett. 33, 1285-1288 Daniels, S. B., Cooney, E., Sofia, M. J., Chakravarty, P. K., and Katzenellen-17.
- bogen, J. A. (1983) J. Biol. Chem. 258, 15046-15053
- 18. Dole, V. P. (1956) J. Clin. Invest. 35, 150-154
- Ibrahim, S. A. (1967) Biochim. Biophys. Acta 137, 413-419 19.
- Diamin, G. A. (1967) *Biotechin. Biophys. Rev. B* **107**, **41**, **51**, 20.
- 21. Lichtenberg, D., Robson, R. J., and Dennis, E. A. (1983) Biochim. Biophys. Acta 737, 285-304
- Silvermann, R. B. (1988) Mechanism-based Enzyme Inactivation, CRC Press, 22. Inc., Boca Raton, FL
- 23. Baek, D. J., and Katzenellenbogen, J. A. (1991) Biochem. Biophys. Res. Commun. 178, 1335-1342
- 24.
- Barbour, S., and Dennis, E. A. (1993) *J. Biol. Chem.* **268**, 21875–21882 Riendeau, D., Guay, J., Weech, P. K., Laliberte, F., Yergey, J., Li, C. 25. Desmarais, S., Perrier, H., Liu, S., and Nicoll-Griffith, D. (1994) J. Biol. Chem. 269, 15619-15624
- 26. Bartoli, F., Lin, H. K., Ghomashchi, F., Gelb, M. H., Jain, M. K., and Apitz-Castro, R. (1994) *J. Biol. Chem.* **269**, 15625–15630 Zupan, L. A., Weiss, R. H., Hazen, S. L., Parnas, B. L., Aston, K. W., Lennon,
- 27. P. J., Getman, D. P., and Gross, R. W. (1993) J. Med. Chem. 36, 95-100